Expected Bleeding After Trans-Perineal Prostate Biopsy
After a trans-perineal prostate biopsy, you should expect hematuria (blood in urine), hematospermia (blood in semen), and hematochezia (blood in stool), with these symptoms typically resolving within 3 to 14 days 1.
Types of Expected Bleeding
The most common bleeding manifestations include:
- Hematuria (blood in urine): Most frequent complication, occurring in 50-80% of patients 2, 3
- Hematospermia (blood in semen): Very common, can persist for several weeks
- Hematochezia (rectal bleeding): Less common with transperineal approach compared to transrectal, occurring in approximately 29-30% of cases 3
Duration of Bleeding
The preponderance of patients will note these bleeding outcomes, and complications typically resolve within 3 to 14 days 1. However, blood in semen may persist longer than urinary or rectal bleeding.
Medication Considerations
Alfuzosin and Tadalafil Impact
Your current medications warrant specific attention:
Alfuzosin 10 mg: As an alpha-blocker, this medication does not significantly increase bleeding risk and can be safely continued 4
Tadalafil 10 mg: The FDA drug label indicates that when tadalafil 20 mg was co-administered with alfuzosin 10 mg, there was minimal blood pressure interaction (mean maximal decrease in standing systolic blood pressure of 4.4 mm Hg) with no severe adverse events related to bleeding 4. At your dose of 10 mg tadalafil, the interaction would be even less significant.
Recent high-quality evidence demonstrates that transperineal prostate biopsy can be performed safely even when patients continue antiplatelet and/or anticoagulation therapy 2, 3. In a 2017 study of 598 patients, those continuing anti-thromboembolic agents showed:
- Hematuria in 59.1% (vs 52.5% in controls, p=0.18)
- Clot retention in only 2.0% of cases
- No Grade III or higher complications 2
More recent 2026 data from 620 patients confirmed that continuing antithrombotic therapy during transperineal biopsy resulted in hemorrhagic events in only 11.7% versus 8.9% in controls (p=0.33), with clinically significant hemorrhage (Clavien-Dindo grade II or higher) being rare at 2.1% 3.
Severity Stratification
Minor bleeding (Grade I): Self-limited hematuria, hematospermia, or rectal spotting requiring no intervention - this is what you should expect
Moderate bleeding (Grade II): Clot retention requiring catheter irrigation or brief hospitalization - occurs in <2% of transperineal cases 2, 3
Severe bleeding (Grade III or higher): Requiring transfusion or surgical intervention - extremely rare with transperineal approach, occurring in <0.5% of cases 1, 2
Critical Warning Signs
Seek immediate medical attention if you experience:
- Inability to urinate (urinary retention)
- Continuous heavy bleeding that doesn't slow after 24 hours
- Dizziness, lightheadedness, or signs of significant blood loss
- Severe abdominal pain (though intraperitoneal bleeding is exceedingly rare with transperineal approach) 5, 6
Practical Management
- Avoid vigorous exercise or heavy lifting for 48-72 hours post-procedure
- Maintain adequate hydration to help flush blood from the urinary system
- Avoid sexual activity until hematospermia resolves (typically 2-4 weeks)
- Continue your alfuzosin and tadalafil as prescribed - no need to discontinue 4, 2
The transperineal approach you're undergoing has a significantly lower infection risk compared to transrectal biopsy and is generally safer regarding bleeding complications 7, 2, 3.